Cargando…

The Muscle Is Not a Passive Target in Myasthenia Gravis

Myasthenia gravis (MG) is a rare autoimmune disease mediated by pathogenic antibodies (Ab) directed against components of the neuromuscular junction (NMJ), mainly the acetylcholine receptor (AChR). The etiological mechanisms are not totally elucidated, but they include a combination of genetic predi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vilquin, Jean-Thomas, Bayer, Alexandra Clarissa, Le Panse, Rozen, Berrih-Aknin, Sonia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930907/ https://www.ncbi.nlm.nih.gov/pubmed/31920954 http://dx.doi.org/10.3389/fneur.2019.01343

Ejemplares similares

Editorial: Advances in Autoimmune Myasthenia Gravis
por: Punga, Anna Rostedt, et al.
Publicado: (2020)

Myasthenia Gravis: An Acquired Interferonopathy?
por: Payet, Cloé A., et al.
Publicado: (2022)

Autoimmune Thyroiditis and Myasthenia Gravis
por: Lopomo, Angela, et al.
Publicado: (2017)

Regulatory B cells in myasthenia gravis are differentially affected by therapies
por: Yilmaz, Vuslat, et al.
Publicado: (2018)

Use of Toll-Like Receptor Agonists to Induce Ectopic Lymphoid Structures in Myasthenia Gravis Mouse Models
por: Robinet, Marieke, et al.
Publicado: (2017)

Circulating miRNAs in myasthenia gravis: miR-150-5p as a new potential biomarker
por: Punga, Tanel, et al.
Publicado: (2014)

Altered expression of fragile X mental retardation-1 (FMR1) in the thymus in autoimmune myasthenia gravis
por: Thomas, Scott, et al.
Publicado: (2021)

Causes and Consequences of miR-150-5p Dysregulation in Myasthenia Gravis
por: Cron, Mélanie A., et al.
Publicado: (2019)

Comparative Analysis of Thymic and Blood Treg in Myasthenia Gravis: Thymic Epithelial Cells Contribute to Thymic Immunoregulatory Defects
por: Truffault, Frédérique, et al.
Publicado: (2020)

Decreased expression of miR-29 family associated with autoimmune myasthenia gravis
por: Cron, Mélanie A., et al.
Publicado: (2020)

Blocking interleukin-23 ameliorates neuromuscular and thymic defects in myasthenia gravis
por: Villegas, José A., et al.
Publicado: (2023)

Novel CXCL13 transgenic mouse: inflammation drives pathogenic effect of CXCL13 in experimental myasthenia gravis
por: Weiss, Julia Miriam, et al.
Publicado: (2016)

New Pathways and Therapeutic Targets in Autoimmune Myasthenia Gravis
por: Behin, Anthony, et al.
Publicado: (2018)

Single-cell mass cytometry on peripheral cells in Myasthenia Gravis identifies dysregulation of innate immune cells
por: Verdier, Julien, et al.
Publicado: (2023)

Patient-reported impact of myasthenia gravis in the real world: protocol for a digital observational study (MyRealWorld MG)
por: Berrih-Aknin, Sonia, et al.
Publicado: (2021)

Patient-reported impact of myasthenia gravis in the real world: findings from a digital observational survey-based study (MyRealWorld MG)
por: Berrih-Aknin, Sonia, et al.
Publicado: (2023)

Extraocular Muscle Atrophy in Myasthenia Gravis
por: Pedapati, Radhakrishna, et al.
Publicado: (2022)

Afterdischarges in Myasthenia Gravis
por: Yang, Li, et al.
Publicado: (2021)

Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG
por: Dewilde, Sarah, et al.
Publicado: (2023)

Novel Treatments in Myasthenia Gravis
por: Menon, Deepak, et al.
Publicado: (2020)

Management of Juvenile Myasthenia Gravis
por: O'Connell, Karen, et al.
Publicado: (2020)

Controversies in Ocular Myasthenia Gravis
por: Evoli, Amelia, et al.
Publicado: (2020)

Immunoregulatory Cells in Myasthenia Gravis
por: Wu, Ying, et al.
Publicado: (2020)

Editorial: Phenotypes of myasthenia gravis
por: Li, Hai-Feng, et al.
Publicado: (2022)

Rituximab treatment in myasthenia gravis
por: Vesperinas-Castro, Ana, et al.
Publicado: (2023)

Role of complement in myasthenia gravis
por: San, Pyae Phyo, et al.
Publicado: (2023)

Role of miRNAs in Normal and Myasthenia Gravis Thymus
por: Cron, Mélanie A., et al.
Publicado: (2020)

IL-6 and Akt are involved in muscular pathogenesis in myasthenia gravis
por: Maurer, Marie, et al.
Publicado: (2015)

Evaluation of the Quantitative Myasthenia Gravis Score and Grip Strength in Chinese Patients With Myasthenia Gravis: An Observational Study
por: Li, Jinghao, et al.
Publicado: (2021)

Comment on “Detecting Key Genes Regulated by miRNAs in Dysfunctional Crosstalk Pathway of Myasthenia Gravis”
por: Le Panse, Rozen
Publicado: (2017)

A Case of Pembrolizumab-Induced Myasthenia Gravis
por: Kosick, Thomas I, et al.
Publicado: (2023)

From Traditional to Targeted Immunotherapy in Myasthenia Gravis: Prospects for Research
por: Mantegazza, Renato, et al.
Publicado: (2020)

Corticosteroid Treatment-Resistance in Myasthenia Gravis
por: Kaminski, Henry J., et al.
Publicado: (2022)

User Involvement in Myasthenia Gravis Research
por: Gilhus, Nils Erik, et al.
Publicado: (2022)

Myasthenia Gravis Presenting as Bulbar Palsy
por: Gosain, Dhruv, et al.
Publicado: (2023)

Treatment of insomnia in myasthenia gravis—A prospective study on non-benzodiazepine hypnotics in the treatment of myasthenia gravis patients with insomnia
por: Yan, Jingwen, et al.
Publicado: (2023)

Inflammation and Epstein-Barr Virus Infection Are Common Features of Myasthenia Gravis Thymus: Possible Roles in Pathogenesis
por: Cavalcante, Paola, et al.
Publicado: (2011)

A Review of Psychiatric Comorbidity in Myasthenia Gravis
por: Law, Christina, et al.
Publicado: (2020)

Determinants of Quality of Life in Myasthenia Gravis Patients
por: Szczudlik, Piotr, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor-Induced Myasthenia Gravis
por: Huang, Yi-Te, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_o55rq5qgr8udqi2gage8rh19ie